ScreenerHero

ALECAlector, Inc.

NAS · US · Healthcare · Biotechnology · alector.com
2.360USD-2.88%Mkt Cap: 263.51M $P/E: —

Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant m…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap263.51M $
Enterprise Value112.30M $
Revenue (TTM)13.86M $
Gross Profit-85.27M $
Net Income (TTM)-142.93M $
Revenue/Share0.1280 USD
Last Price2.360 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees103
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS0144421072
Valuation
P/E (Trailing)—
P/E (Forward)-3.03
PEG—
EV/EBITDA-0.94
EV/Revenue8.10
P/S18.20
P/B-25.39
EPS (TTM)-1.01
EPS (Forward)-0.75
52W Range
1.09055% of range3.400
52W High3.400 USD
52W Low1.090 USD
Profitability
Gross Margin0.00%
Oper. Margin-734.73%
EBITDA Margin0.00%
Profit Margin-679.16%
ROE-466.34%
ROA-48.74%
Growth
Revenue Growth-57.80%
Earnings Growth—
Cash Flow & Leverage
Operating CF-184.03M $
CapEx (TTM)41.00K $
FCF Margin-773.66%
FCF Yield-40.70%
Net Debt-140.04M $
Net Debt/EBITDA1.18
Balance Sheet
Debt/Equity1.18
Current Ratio5.26
Quick Ratio5.05
Book Value/Sh-0.0890 USD
Cash/Share1.548 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.6 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)3.100 USD
Upside (mean)+31.4%
Target Range1.000 USD – 6.000 USD
$1.000+31.4% to mean$6.000
# Analysts5
Ownership
Shares Out.111.66M
Float94.43M
Insiders9.61%
Institutions84.91%
Short Interest
Short Ratio11.2d
Short % Float5.35%
Short % Out.5.06%
Shares Short5.64M
Short (prev mo.)5.72M
Technical
SMA 501.734 (+36.1%)
SMA 2001.862 (+26.8%)
Beta0.58
S&P 52W Chg18.16%
Avg Vol (30d)1.03M
Avg Vol (10d)2.04M
Technical Indicators
RSI (14)67.4
MACD0.1541
MACD Signal0.0718
MACD Hist.+0.0823
BB Upper2.406 USD
BB Middle1.778 USD
BB Lower1.151 USD
BB Width70.57%
ATR (14)0.2010 USD
Vol Ratio (20d)0.59x